ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with bullous pemphigoid (BP), a phase 2/3 study demonstrated. “Dupilumab demonstrated significant benefits across multiple disease aspects in BP at 36 weeks...
256 W Beech St P.O. Box 32 Harrison, Michigan, USA 48625
(989) 424-9929
austin@clippershipsandcaravans.com
Copyright © 2023 roenews2. All Rights Reserved
